Next Article in Journal
Inhibition of Human Transthyretin Aggregation by Non-Steroidal Anti-Inflammatory Compounds: A Structural and Thermodynamic Analysis
Previous Article in Journal
The Study of Dynamical Potentials of Highly Excited Vibrational States of HOBr
Int. J. Mol. Sci. 2013, 14(3), 5264-5283; doi:10.3390/ijms14035264
Review

Caffeic Acid Phenethyl Ester as a Potential Treatment for Advanced Prostate Cancer Targeting Akt Signaling

1,2,†
, 1,2,3,†
, 4,5,6,†
, 1,2
, 1,2,7
, 1,2
, 1,8
, 9
, 10 and 1,2,11,12,*
Received: 30 January 2013; in revised form: 19 February 2013 / Accepted: 28 February 2013 / Published: 6 March 2013
View Full-Text   |   Download PDF [692 KB, uploaded 19 June 2014]   |   Browse Figures
Abstract: Prostate cancer is the fifth most common cancer overall in the world. Androgen ablation therapy is the primary treatment for metastatic prostate cancer. However, most prostate cancer patients receiving the androgen ablation therapy ultimately develop recurrent castration-resistant tumors within 1–3 years after treatment. The median overall survival time is 1–2 years after tumor relapse. Chemotherapy shows little effect on prolonging survival for patients with metastatic hormone-refractory prostate cancer. More than 80% of prostate tumors acquire mutation or deletion of tumor suppressor phosphatase and tensin homolog (PTEN), a negative regulator of PI3K/Akt signaling, indicating that inhibition of PI3K/Akt might be a potential therapy for advanced prostate tumors. Caffeic acid phenethyl ester (CAPE) is a strong antioxidant extracted from honeybee hive propolis. CAPE is a well-known NF-κB inhibitor. CAPE has been used in folk medicine as a potent anti-inflammatory agent. Recent studies indicate that CAPE treatment suppresses tumor growth and Akt signaling in human prostate cancer cells. We discuss the potential of using CAPE as a treatment for patients with advanced prostate cancer targeting Akt signaling pathway in this review article.
Keywords: prostate cancer; caffeic acid phenethyl ester; Akt; LNCaP; PC-3 prostate cancer; caffeic acid phenethyl ester; Akt; LNCaP; PC-3
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Lin, H.-P.; Lin, C.-Y.; Liu, C.-C.; Su, L.-C.; Huo, C.; Kuo, Y.-Y.; Tseng, J.-C.; Hsu, J.-M.; Chen, C.-K.; Chuu, C.-P. Caffeic Acid Phenethyl Ester as a Potential Treatment for Advanced Prostate Cancer Targeting Akt Signaling. Int. J. Mol. Sci. 2013, 14, 5264-5283.

AMA Style

Lin H-P, Lin C-Y, Liu C-C, Su L-C, Huo C, Kuo Y-Y, Tseng J-C, Hsu J-M, Chen C-K, Chuu C-P. Caffeic Acid Phenethyl Ester as a Potential Treatment for Advanced Prostate Cancer Targeting Akt Signaling. International Journal of Molecular Sciences. 2013; 14(3):5264-5283.

Chicago/Turabian Style

Lin, Hui-Ping; Lin, Ching-Yu; Liu, Chun-Chieh; Su, Liang-Cheng; Huo, Chieh; Kuo, Ying-Yu; Tseng, Jen-Chih; Hsu, Jong-Ming; Chen, Chi-Kuan; Chuu, Chih-Pin. 2013. "Caffeic Acid Phenethyl Ester as a Potential Treatment for Advanced Prostate Cancer Targeting Akt Signaling." Int. J. Mol. Sci. 14, no. 3: 5264-5283.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert